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Abstract
Background: In a retrospective study of HIV-infected patients, we investigated the influence of
the MDR1 genotype (G2677T/A and C3435T) on the virological and immunological response of
treatment naïve patients.
Methods: The MDR1 genotype was analysed from 72 patients in whom antiretroviral therapy was
initiated between 1998 and 2004. Data were obtained at week 4, 12, 24 and 48 and were analysed
by the Kruskal-Wallis test.
Results: During the first 48 weeks of antiretroviral therapy, there were no significant differences
in the virological and immunological response with respect to the MDR1 2677 and 3435 genotypes
and the 2677/3435 haplotype.
Conclusions: In view of different results from several studies concerning the influence of MDR1
polymorphisms on the immunological and virological response to antiretroviral therapy, further
studies with larger patient groups and longer follow-up are necessary in order to resolve conflicting
issues.
Background
The P-glycoprotein (P-gp) is an ATP-dependent efflux
transporter (ABCB1) encoded by the multidrug resistance
gene (MDR1) which extrudes large lipophilic, positvely
charged molecules from cells, among them HIV-1 pro-
tease inhibitors [1,2]. P-gp is expressed on a variety of cells
including human lymphocytes, the target cells of HIV and
of antiretroviral substances [3]. 48 single nucleotide poly-
morphisms (SNP) have been described so far for the
MDR1 gene [4]. Though there is still controversy about
the biological relevance of these SNPs, there appears to be
an association between specific genotypes and mRNA
expression, P-gp expression and/or P-gp function
(reviewed in [5,6]). Recently, Fellay et al. found lower
nelfinavir and efavirenz plasma levels associated with the
TT genotype of the SNP C3435T in exon 26 and a greater
rise of the CD4 cell count 6 months after initiation of
antiretroviral therapy in patients with this genotype [7].
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However, the mechanisms underlying this observation
remain unclear. In contrast to protease inhibitors (PI),
non-nucleoside reverse transcriptase inhibitors (NNRTI)
such as efavirenz are not substrates of the P-gp. Therefore,
it has been speculated that the P-gp may modulate the
clinical course of HIV infection independent from its role
in drug transport. Indeed, there have been reports show-
ing inhibition of apoptosis and decreased HIV production
in cells overexpressing P-gp [8-12]. However, these obser-
vations from in vitro studies have not been confirmed in
vivo when the disease progression before treatment was
assessed in HIV infected individuals with different MDR1
genotypes [13].
The genetic variant C3435T in exon 26 is a synonymous
polymorphism that does not alter the amino acid
sequence. How this variant could affect P-gp expression is
still unknown [6]. According to one hypothesis, func-
tional effects of the C3435T SNP may not be genotype-
but haplotype-dependent. The exon 26 C3435T polymor-
phism is in linkage disequlibrium with the polymorphism
G2677T in exon 21, which results in the amino acid
change Ala893Ser [6]. 2677A leading to Ala893Thr is an
infrequent third allel of this SNP. The results of several
studies on the functional effects of mutations at position
2677 in exon 21 have shown conflicting results [6].
Because of the unresolved issues surrounding the poten-
tial effects of MDR1 polymorphisms and P-gp function in
HIV infection, we investigated whether there was an asso-
ciation between the MDR1 polymorphisms 3435 and
2677 and the immunological response in HIV infected
individuals after initiation of antiretroviral therapy.
Methods
Patients
Of the HIV 1 infected patients seen at the Department of
Infectious Diseases of the University of Würzburg, Ger-
many, 72 patients (18 women, 54 men; mean age 39.5
years, range: 26 – 59 years; 64 Caucasians, 5 African, 3
Asian), started antiretroviral therapy between 1998 and
2004. The therapy consisted of three nucleoside reverse
transcriptase inhibitors (NRTI) (n = 12), two NRTIs plus
at least one PI (n = 40; including RTV n = 26) or two NRTIs
plus one NNRTI (n = 20). HIV load and CD4 cell count
were determined four weeks after initiation of therapy and
approximately every three months thereafter. In patients
who received NNRTI or PI drugs as part of their therapy,
plasma levels were monitored and adjusted to therapeutic
drug levels when necessary as previously described
[14,15]. The treatment was based on current international
treatment guidelines [16], taking into account individual
circumstances of each patient (e.g. known intolerabilities,
side-effects of previous therapies, concomitant
medication).
The study was in accordance with the Helsinki Declara-
tion and was approved by the local ethics committee.
Patients gave informed consent for the study.
Genotype analysis
DNA was extracted from 200 µl blood and the MDR1
3435 genotype was determined with genotype specific
hybridisation probes and melting curve analysis on the
LightCycler (Roche, Mannheim, Germany) as previously
described [17]. The 2677 genotype was determined in a
similar fashion [18]. Briefly, DNA was amplified on the
LightCycler with the Quantitect Probe PCR Kit (Qiagen,
Hilden, Germany) by using the primers 5'-gcaggagttgtt-
gaaatgaaaatg-3' (forward) and 5'-cgcctgctttagtttgactca-3'
(reverse). Hybridization probes were added to the master
mix to a final concentration of 0.05 µM (sensor probe: 5'-
ttcccagTaccttct-fluorescein; locked nucleic acid base in
upper case letter) and 0.15 µM (anchor probe: 5'-LC
Red640-ctttcttatctttcagtgcttgtcc-p). Primers and probes
were obtained from TIB Molbiol (Berlin, Germany). The
melting points were 41°C, 47°C, and 52°C for the T-, G-
, and A-alleles, respectively. The results of 30 samples were
confirmed by sequencing.
Statistical analysis
Data were analysed by the Kruskal-Wallis test, which as a
nonparametric test compairs three or more unpaired
groups. Because of the small number of samples a nonpar-
ametric test was needed. SPSS version 12.0 (SPSS GmbH,
Munich, Germany) was used for statistical analysis. A P-
value of 0.05 was considered to be significant. Analogous
to [13], the SNPs 3435 and 2677 were analyzed both sep-
arately and in combination as composite genotypes: H1:
2677GG and 3435CC (wild type); H2: 2677GT or TT and
3435CT or TT (2677T/3435T haplotype carrier); H3:
2677GG and 3435CT or TT; H4: 2677GT or TT and
3435CC; and H5: 2677AG or AT and any 3435 genotype
(2677A carrier).
Results
At initiation of antiretroviral therapy 8 patients had viral
loads of <10.000 copies/ml, 24 patients between >10.000
and <100.000 copies/ml, and 40 patients >100.000 cop-
ies/ml. 39 patients had a CD4 cell count of <200 cells/µl,
16 patients between >200 and <350 cells/µl, and 17
patients >350 cells/µl. Determination of NNRTI- and PI
drug levels indicated compliance of the patients with a
NNRTI or PI containing regimen, because the measured
drug levels were in the therapeutic range. Genotype anal-
ysis of the MDR1 gene at position 3435 in exon 26
revealed 20 patients with the CC genotype, 33 with the CT
genotype and 19 with the TT genotype (5 patients of Afri-
can origin: 4 with CC and 1 with CT genotype; 3 patients
o f Asisan origen: 2 with CT and 1 with TT genotye). Anal-
ysis of the 2677 polymorphism in exon 21 demonstratedAnnals of Clinical Microbiology and Antimicrobials 2005, 4:3 http://www.ann-clinmicrob.com/content/4/1/3
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that 24 patients had the GG-, 23 the GT-, 18 the TT-, 4 the
AG-, and 3 the AT genotype; the AA genotype was not
found in this group (5 patients of African origin: 4 with
GG and 1 with GT genotype; 3 patients of Asian origin: 3
with TT genotype). Detailed genotype and haplotype
results with respect to the initial viral load and CD4 cell
count are presented in table 1.
Table 2 and 3 show the median and mean values of the
viral load decline and the CD4-cell increase, respectively,
determined at week 4, 12, 24 and 48 after initiation of
therapy. There were no significant differences of the viral
load decline neither between patient groups with different
genotypes at positions 2677 or 3435 nor between patient
groups with different 2677/3435 haplotypes. As to the
CD4-cell response, there were no significant differences
between the different genotypes and haplotypes, either.
There was a trend of a more pronounced mean CD4-cell
increase at week 12 and 24 in patients with the 3435TT
genotype. However, this trend did not persist at week 48
and was not confirmed by the corresponding median val-
ues. A graphical presentation of the mean viral load
decrease and CD4-cell increase with respect to the 2677/
3435 haplotypes is given in fig. 1. Analysis of patients
with different therapy-regimens (only NRTI, NRTI +
NNRTI, or NRTI + PI) revealed no differences in the viro-
logical and immunological response between the differ-
ent genotypes either, but was limited by small patient
numbers in the subgroups (data not shown).
Discussion
In an analysis of the virological and immunological
response of treatment naïve patients with respect to the
MDR1 G2677T/A and C3435T polymorphisms, virus load
and CD4 cell count were assessed longitunally after initi-
ation of antiretroviral therapy. We did not find an associ-
ation between the CD4-cell increase or the HIV load
decline and the MDR1 2677 or 3435 genotype during the
first year of therapy.
Our data are in contrast to a report of Fellay et al. that
showed a significantly greater mean CD4-cell rise in
patients with the MDR1 3435TT genotype during an
observation period of 24 weeks [7]. The number of
patients in the previous report (n = 96) was slightly larger
than our population (n = 72), but the number of homozy-
gotes of the 3435 polymorphism was very similar (22CC/
20TT in [7], 20CC/19TT this study). Though we saw a
trend towards a greater mean CD4-cell rise in patients
with the 3435TT genotype as well, we doubt that this is
indication of a real difference, because this trend was not
seen when median values were considered. In our study,
neither median values nor mean values were significantly
different by Kruskal-Wallis test and ANOVA, respectively.
For genotype subgroup sizes as in this study, analysis of
the mean values is probably less robust. If there was a real
difference between the immunological response of
patients with the 3435CC and TT genotype, it did not per-
sist at week 48. At this time point, mean and median val-
ues in the two groups were almost identical. A possible
explanation for the diverse results is the selection of the
study patients. While we included all treatment naïve
patients in whom therapy was started between 1998 and
2004, Fellay et al. selected part of the patients on the basis
of long-term viral suppression. In both studies, a variety of
antiretroviral regimens was used. While all of the patients
Table 1: Genotype analysis of 72 treatment naive HIV-positive patients with respect to baseline CD4 cell count and viral load.
CD4 [cells/µl] VL [copies/µl] n = 2677 3435 2677/3435$
GG GT TT AG AT AA CC CT TT H1 H2 H3 H4 H5
<200 >105 27 7 7 8 3 2 - 7 10 10 5 15 2 - 5
104 – 105 8431---26-242--
<104 4211---12 1 121--
200 >105 6231---14 1 141--
-350 104 – 105 9333---33 3 36---
<104 11-----1--1----
>350 >105 7142---13 3 16---
104 – 105 712211-24114--2
<104 33-----21-2-1--
total 72 24 23 18 4 3 0 20 33 19 17 41 7 - 7
$composite genotypes: H1: 2677GG and 3435CC (wild type); H2: 2677GT or TT and 3435CT or TT (2677T/3435T haplotype carrier); H3: 
2677GG and 3435CT or TT; H4: 2677GT or TT and 3435CC; and H5: 2677AG or AT and any 3435 genotype (2677A carrier)Annals of Clinical Microbiology and Antimicrobials 2005, 4:3 http://www.ann-clinmicrob.com/content/4/1/3
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in the study of Fellay et al. received either nelfinavir or efa-
virenz, the treatment regimens in our study were more
heterogenous and did not allow a meaningful separate
analysis.
The results of our study are supported by Nasi et al. [19]
who analysed data of 149 treatment naïve patients who
were treated with a PI-containing regimen (n = 106) or a
NNRTI-containing regimen (n = 46) and found no associ-
Table 2: VL-decrease [log copies/ml] at week 4, 12, 24 and 48 after initiation of antiretroviral therapy with respect to the MDR1 2677 
and 3435 genotypes. Statistical analysis was done with the Kruskall-Wallis test.
week 4 week 12 week 24 week 48
MDR1 n = median 
[log/ml]
mean 
[log/ml]
SA p =n  =m e d i a n  
[log/ml]
mean 
[log/ml]
SA p =n  = m e d i a n  
[log/ml]
mean 
[log/ml]
SA p =n  =m e d i a n  
[log/ml]
mean 
[log/ml]
SA p =
2677 GG 22 -2,301 -2,210 0,590 >0.3 22 -3,048 -3,287 0,682 >0.05 20 -3,943 -3,876 0,748 >0.9 15 -3,716 -3,835 0,777 >0.5
GT 21 -2,602 -2,537 0,566 19 -3,786 -3,794 0,635 17 -3,929 -3,933 0,499 16 -3,942 -3,946 0,488
TT 17 -2,495 -2,372 0,651 16 -3,739 -3,602 0,595 17 -4,000 -3,850 0,708 14 -3,977 -3,795 0,615
AG 3 -2,301 -2,689 0,606 § 4 -3,952 -4,167 0,884 § 4 -4,500 -4,537 0,702 § 4 -4,151 -4,362 0,726 §
AT 3 -1,875 -2,032 0,493 § 3 -4,176 -3,752 0,690 § 3 -4,176 -4,085 0,223 § 3 -4,176 -4,085 0,223 §
3435 CC 17 -2,301 -2,382 0,501 >0.6 19 -3,301 -3,416 0,699 >0.4 17 -4,000 -3,974 0,685 >0.7 13 -3,716 -3,818 0,709 >0.6
CT 32 -2,247 -2,363 0,640 29 -3,778 -3,742 0,737 28 -3,812 -3,830 0,704 25 -3,929 -3,984 0,614
TT 17 -2,398 -2,348 0,668 17 -3,602 -3,530 0,595 17 -4,176 -4,054 0,571 15 -4,114 -3,849 0,609
2677
/
3435
†
H1 15 -2,398 -2,398 0,531 >0.8 16 -3,199 -3,361 0,724 >0.08 14 -3,943 -3,926 0,715 >0.8 10 -3,659 -3,774 0,787 >0.4
H2 38 -2,548 -2,463 0,611 35 -3,778 -3,706 0,624 34 -3,954 -3,891 0,614 30 -3,954 -3,875 0,556
H3 7 -1,778 -1,806 0,502 § 6 -2,827 -3,089 0,506 § 6 -3,827 -3,761 0,807 § 5 -4,176 -3,958 0,741 §
H5 6 -2,261 -2,361 0,642 § 7 -4,176 -3,989 0,833 § 7 -4,301 -4,343 0,594 § 7 -4,176 -4,243 0,584 §
total 66 64 61 52
†composite genotypes: see methods; §excluded from statistical analysis
Table 3: CD4-cell increase [cells/µl] at week 4, 12, 24 and 48 after initiation of antiretroviral therapy with respect to the MDR1 2677 
and 3435 genotypes. Statistical analysis was done with the Kruskall-Wallis test.
week 4 week 12 week 24 week 48
MDR1 n = median 
[cells/µl]
mean 
[cells/µl]
SA p =n  =m e d i a n  
[cells/µl]
mean 
[cells/µl]
SA p =n  =m e d i a n  
[cells/µl]
mean 
[cells/µl]
SA p =n  =m e d i a n  
[cells/µl]
mean 
[cells/µl]
SA p =
2677 GG 24 56,5 69,8 81,5 >0.3 22 97,0 130,6 132,4 >0.5 21 107,0 136,1 120,5 >0.8 15 244,0 235,7 132,1 >0.1
GT 23 24,0 37,8 82,5 20 84,5 144,3 157,2 17 132,0 180,8 178,0 16 161,5 238,3 218,6
TT 18 9,5 67,4 117,7 16 70,0 143,9 222,3 16 95,0 154,5 162,0 14 107,5 143,9 159,1
AG 4 70,5 85,8 68,5 § 4 82,5 74,8 34,4 § 4 54,5 80,3 81,3 § 4 131,5 126,5 71,0 §
AT 3 112,0 105,7 13,4 § 3 176,0 180,7 63,8 § 2 154,5 154,5 54,5 § 3 172,0 248,0 118,2 §
3435 CC 20 76,0 84,8 78,6 >0.1 19 91,0 123,0 113,0 >0.9 18 106,5 132,4 112,4 >0.5 13 191,0 220,1 121,5 >0.6
CT 34 25,5 47,2 76,1 30 85,0 123,7 135,3 28 131,0 134,2 106,8 25 159,0 187,7 118,4
TT 18 12,0 61,6 119,1 17 74,0 175,9 228,1 16 134,0 212,2 214,7 15 122,0 223,9 259,3
2677/3435† H1 17 72,0 83,1 78,7 >0.1 16 115,0 132,1 119,8 >0.8 15 107,0 142,2 113,3 >0.9 10 194,0 239,6 128,4 >0.5
H2 41 20,0 50,8 100,6 36 74,5 144,1 188,9 33 130,0 168,1 170,9 30 134,5 194,2 198,8
H3 7 19,0 37,3 79,1 § 6 92,0 126,7 161,2 § 6 122,0 120,8 135,7 § 5 302,0 227,8 138,9 §
H5 7 87,0 94,3 53,5 § 7 105,0 120,1 71,9 § 7 100,0 131,0 98,7 § 7 172,0 178,6 111,7 §
total 72 65 61 52
†composite genotypes: see methods; §excluded from statistical analysisAnnals of Clinical Microbiology and Antimicrobials 2005, 4:3 http://www.ann-clinmicrob.com/content/4/1/3
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ation between the MDR1 genotype at position 3435 and
the CD4 cell increases or plasma viral load decreases dur-
ing the first six months of treatment among individuals
with different genotypes. Likewise, in 142 patients
enrolled in an open-label, randomized phase IIIb study
comparing nelfinavir and efavirenz for treatment of
HAART-naïve individuals the CD4 cell counts did not
increase to a higher level in individuals with the
Composite genotypes (see methods) and response to antiretroviral treatment Figure 1
Composite genotypes (see methods) and response to antiretroviral treatment. Suppression of viraemia (lower panel) and 
CD4-cell count increase (upper panel) are shown. Data are mean values ± standard error.Annals of Clinical Microbiology and Antimicrobials 2005, 4:3 http://www.ann-clinmicrob.com/content/4/1/3
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homozygous variant genotype (TT) at the MDR1 C3435T
locus in either the nelfinavir or the efavirenz treatment
groups [20].
The MDR1 3435 polymorphism is a synonymous poly-
morphism. The TT genotype may have a reduced transla-
tion efficiency or lead to post-translational differences
[21-23]. It has been shown, that a linkage disequilibirum
exists between the exon 26 C3435T and the exon 21
G2677T/A polymorphism [6]. Therefore, we investigated
both SNPs in our study. Neither the 2677 polymorphism
alone nor the 2677/3435 haplotype was associated with
differences in the virological or immunological response
of treatment naïve patients. These data are in agreement
with those of Haas et al. [24], who showed that the phase
1 and phase 2 viral decay as well as changes in CD4- and
CD8-T-cells during triple therapy with ritonavir, zidovu-
dine, and lamivudine in 31 treatment naïve patients were
not associated with the MDR1 2677 and 3435 genotypes.
In a retrospective study of 455 treatment naïve patients
initiating antiretroviral therapy with 40 months of follow-
up [25], there was a trend to earlier virological failure in
the 3435CC group (p = 0.07) with no effect of the C3435T
polymorphism in the MDR-1 gene on immunological
failure. However, the difference in the virological
response was not observed during the first 10 months.
Further follow-up of our patient group is ongoing in order
to detect long-term effects that may not have been appar-
ent during the observation period analysed in this report.
Conclusions
During a follow-up of 48 weeks, we found no evidence for
an association between the MDR1 G2677T/A and C3435T
polymorphisms and the virological and immunological
response to therapy in HIV-positive drug-naïve patients.
The individual response to antiretroviral therapy is a com-
plex phenomenon, which is influenced by a large number
of biological variables. Further studies on the role of pol-
ymorphisms of the MDR1 and other transporters and
enzymes involved in drug metabolism are necessary in
order to elucidate the role of pharmacogenetic effects in
HIV therapy.
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